---
title: "Obefazimod (ABX464) in Ulcerative colitis: Interleukin-12/23 inhibitors"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Interleukin-12/23 inhibitors. Topics: Recommendations for ustekinumab: ACG 2025 guideline, UNIFI pivotal trial efficacy of ustekinumab: ACG 2025 guideline, Comparative efficacy of ustekinumab after prior advanced therapy: AGA 2024 living guideline, Recommendations and trial results for ustekinumab: ECCO 2026 guideline, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/interleukin-12-23-inhibitors"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Interleukin-12/23 inhibitors

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Interleukin-12/23 Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

### Recommendations for ustekinumab: ACG 2025 guideline

> “25. In patients with moderately to severely active UC, we recommend the interleukin (IL)-12/23p40 antibody ustekinumab for induction of remission (Strong recommendation, moderate quality of evidence).”
> “39. We recommend continuing ustekinumab for maintenance of remission as compared to no treatment in patients who responded to the induction dose of this medication (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.6-2"></a>

### UNIFI pivotal trial efficacy of ustekinumab: ACG 2025 guideline

> “At week 8, a larger proportion of patients who received ustekinumab 6 mg/kg (15.5%) achieved clinical remission compared with placebo (5.3%, P < 0.001).”
> “Among responders to ustekinumab induction, patients who were maintained on ustekinumab 90 mg subcutaneously every 8 weeks were more likely to be in clinical remission after 44 weeks (43.8%) compared with those assigned to placebo (24.8%, P < 00.08).”
> “There were no differences in serious adverse events between treatment and placebo groups, and notably, placebo-exposed patients had increased rates of disease-related adverse events.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.6-3"></a>

### Comparative efficacy of ustekinumab after prior advanced therapy: AGA 2024 living guideline

> “Ustekinumab demonstrated a likely important benefit over adalimumab, vedolizumab, ozanimod, etrasimod, and mirikizumab with a moderate certainty of evidence.”
> “Biosimilars of infliximab, adalimumab, and ustekinumab can be considered equivalent to their originator drug in their efficacy in terms of therapy selection.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

<a id="topic-2.2.2.1.6-4"></a>

### Recommendations and trial results for ustekinumab: ECCO 2026 guideline

> “We recommend treatment with ustekinumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend ustekinumab for the maintenance of remission in patients with ulcerative colitis who responded to induction therapy with ustekinumab [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “Of these, 51.6% of randomized patients had previously failed treatment with an alternative biologic, including 18% who failed treatment with both an anti-TNF agent and vedolizumab. The study demonstrated the benefit of ustekinumab [6 mg/kg] over placebo in induction of clinical remission [RR: 2.91; 95% CI: 1.72–4.94], clinical response [RR: 1.97; 95% CI: 1.64–2.37], and endoscopic improvement [RR: 1.96; 95% CI: 1.41–2.72].”
> “SAEs did not differ between ustekinumab and placebo [RR: 0.67; 95% CI: 0.39–1.17].”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.6-5"></a>

### Indication and warnings for ustekinumab

> “STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.”
> “Infections: Serious infections have occurred.”
> “Tuberculosis (TB): Evaluate patients for TB prior to initiating treatment with STELARA.”
> “Malignancies: STELARA may increase risk of malignancy.”
> “Posterior Reversible Encephalopathy Syndrome (PRES): If PRES is suspected, treat promptly, and discontinue STELARA.”

Source: [Stelara prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125261s173lbl.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
